In the clinic, therapeutic effects for BA analogs and synthetic FXR agonists on various liver injury and metabolic disorders, including primary biliary cholangitis, nonalcoholic fatty liver disease, nonalcohol hepatitis, and lipodystrophy, have been reported [51]. The gene discussed is NR1H4; the disease is metabolic disease.